Realheart reports ~6x lower hemolysis versus market TAH
Scandinavian Real Heart AB says peer-reviewed preclinical lab data show its Realheart TAH caused about six times less hemolysis than a widely used FDA-approved artificial heart model; von Willebrand factor function was preserved.